+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07046078

Study of FLAG-Ida Chemotherapy Followed by Lower-Dose Total Body Radiation and Donor Stem Cell Transplant in Adults 60 and Older with High-Risk Acute Myeloid Leukemia or Other Serious Myeloid Cancers

Led by Fred Hutchinson Cancer Center · Updated on 2026-07-20

20

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a treatment approach for adults age 60 and older with newly diagnosed adverse-risk acute myeloid leukemia AML or other high-grade myeloid cancers. The study focuses on testing the safety, side effects, and effectiveness of combination chemotherapy called FLAG-Ida followed by reduced-intensity total body irradiation TBI and donor hematopoietic cell transplant HCT. Despite advances in care, outcomes for these patients are poor, and this study explores a new strategy to reduce risks related to low blood cell counts and improve treatment success. Participants receive granulocyte colony-stimulating factor G-CSF subcutaneously daily, along with intravenous fludarabine, high-dose cytarabine, and idarubicin on specified days. This is followed by reduced-intensity TBI given once or twice daily. Then, patients undergo allogeneic HCT with peripheral blood stem cells. Treatment continues as long as the disease does not progress or unacceptable side effects occur. The study also includes procedures like heart scans MUGA or echocardiography, bone marrow biopsies, and blood sample collections. During the study, participants are monitored with bone marrow exams and blood tests. Follow-up visits occur at days 28, 56, and 80, then at months 3 and 6, and years 1 and 2 after treatment. Researchers measure outcomes such as how many patients start treatment within 42 days, transplant rates, recovery of blood cells, adverse events, graft-versus-host disease, remission rates, and survival. Safety and long-term effects are carefully observed throughout this period.

CONDITIONS

Brief Title

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Research Team

F

Filippo Milano, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here